Helix BioPharma closes $1.66-million private placement

Executive Summary

• Helix BioPharma Corp. has closed a non-brokered private placement of 2,222,333 common shares for gross proceeds of $1,666,750.
• This transaction represents the second phase of the company's bridge financing strategy, following a $3-million placement announced in January 2025.
• Net proceeds will be used for near-term development activities and working capital, supporting the company's goal of securing larger institutional investment and an uplisting to Nasdaq.

Key Details

• Transaction Structure: Non-brokered private placement of common shares.
• Quantity: 2,222,333 common shares.
• Price: $0.75 per common share.
• Gross Proceeds: $1,666,750.
• Use of Proceeds: Near-term development activities and working capital.
• Strategic Context: Part of a bridge financing strategy to advance toward institutional investment and a Nasdaq uplisting.
• Regulatory Status: Subject to final approval of the Toronto Stock Exchange (TSX).
• Hold Period: Common shares are subject to a hold period of four months and one day, expiring on December 23, 2025.
• Finder's Fees: The company will pay finders' fees to certain eligible finders in connection with the closing.
• Future Plans: The company intends to launch the next private placement once new price protection approval is granted by the TSX.

Notable Quotes

• No direct quotes from executives were included in the provided text.